BGI Genomics

BGI Genomics BGI Genomics is the world’s leading integrated solutions provider of precision medicine

BGI Genomics provides academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic sequencing and proteomic services and solutions across a broad range of applications spanning:

• Basic research covering human, plant, animal and microbial species
• Clinical research in human health
• Drug discovery and development
• Agriculture and Biodive

rsity preservation and sustainability

We have almost 20 years of genomics experience helping our customers achieve their research goals by delivering rapid, high quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBSEQ™ sequencing technology.

🎉Great experience at the 3-day conference in Norwich, UK (Jun 2-Jun 4)!Hang(Leo) CHEN and Huijuan Chen (Jean) from our...
09/06/2026

🎉Great experience at the 3-day conference in Norwich, UK (Jun 2-Jun 4)!

Hang(Leo) CHEN and Huijuan Chen (Jean) from our team were on-site to demonstrate our end-to-end solutions. It was a pleasure connecting with fellow experts across plant and microbial science communities.

Thank you to everyone who joined us for insightful technical talks and idea sharing. We’re excited to advance future collaborations together! 👋

Nature Study: WGS Detects 42% of Confirmed Disorders Missed by Routine Newborn Screening. 🧬👶A large Chinese cohort study...
05/06/2026

Nature Study: WGS Detects 42% of Confirmed Disorders Missed by Routine Newborn Screening. 🧬👶

A large Chinese cohort study, jointly conducted by BGI Genomics, Fudan University, Qingdao Women and Children's Hospital, enrolled 9,992 newborns, comparing WGS against the conventional newborn screening method.

📄Key findings:
🔹 42% of confirmed disorders were completely missed by routine methods
🔹 Reanalysis power: 8 of 19 initially negative infants diagnosed later – including de novo mutations
🔹 Fewer false positives: WGS clarified 11 biochemical false positives, sparing families unnecessary anxiety
🔹 Actionable early warnings: Identified FH carriers, MT-RNR1 drug-induced deafness risk, and other disorders not covered by routine panels

The takeaway: WGS can complement the current newborn screening with higher accuracy.

Read the full study 👇
https://www.bgi.com/global/news/wgs-detects-42-of-confirmed-disorders-missed-by-routine-newborn-screening-nature-health

From molecules to megabytes, showcased how AI, big data, and are reshaping the future of life science. 🧬✨Over the la...
05/06/2026

From molecules to megabytes, showcased how AI, big data, and are reshaping the future of life science. 🧬✨

Over the last week in , we had the pleasure of connecting with researchers and innovators exploring everything from spatial biology and analysis to precision medicine and AI-driven discovery.

Jingjing(Yilia) Huo, Yanhong Wang and Ziyun Wang saw strong interest in at our booth. That's a clear sign that is becoming essential for studying cellular interactions, tissue architecture, and disease mechanisms. 🔬

A big thank you to everyone who stopped by, shared their research, and discussed future collaboration opportunities. The passion and innovation across the scientific community continue to inspire us.

See you soon. 🙌

Last week, we were honored to participate in the 2nd International Symposium on Chemical & Biomedical Imaging (CBMI-II),...
04/06/2026

Last week, we were honored to participate in the 2nd International Symposium on Chemical & Biomedical Imaging (CBMI-II), hosted by The Hong Kong Polytechnic University - PolyU

We were delighted to exchange ideas with distinguished scientists, such as Professor Zijian Guo, Vice-Chair of CBMI-II, and exchange perspectives on the future of research and innovation.

During the symposium, Dr. Yanhong Wang, R&D Director at , shared recent advances in and technologies, highlighting how these approaches complement imaging-based research and provide deeper insights into complex biological systems.

This symposium brought together researchers and innovators from the fields of chemical imaging, , biomedical engineering, and in .

Thank you to everyone who joined the discussions and shared their expertise. We look forward to seeing you at the next one! 🚀

Underused PCR lab？BGI Sample Star-16 transforms it to a working colorectal cancer screening service - Client StoryMany P...
03/06/2026

Underused PCR lab？BGI Sample Star-16 transforms it to a working colorectal cancer screening service - Client Story

Many PCR labs have the space, equipment, and skilled staff – but fluctuating testing demand leaves capacity idle.

A municipal hospital in China turned that underused lab into a daily colorectal cancer screening workflow using BGI Sample Star‑16 for automated nucleic acid extraction.

The result:
✅ Scalable throughput – ~26 samples/day with one technologist
✅ Operational consistency – automated pre‑analytical steps reduce manual variation
✅ Low recollect rate – only 10 of ~900 stool samples needed re‑testing
✅ Clinical impact – 12 of 15 colonoscopy‑positive cases detected adenomas

Key takeaway for labs:
Stool DNA methylation testing + automation turns existing PCR capacity into a sustainable, high‑value cancer prevention service.

📖 Read the full case study: https://www.bgi.com/global/news/bgi-sample-star-16-helps-pcr-labs-build-local-colorectal-cancer-screening-workflows

On May 27, the American Cancer Society formally elevated multitarget stool DNA (mt-sDNA) tests to a preferred colorectal...
29/05/2026

On May 27, the American Cancer Society formally elevated multitarget stool DNA (mt-sDNA) tests to a preferred colorectal cancer ( ) screening modality for average‑risk adults starting at age 45, right before hashtag .

That means non‑invasive, accessible screening is no longer a nice-to-have – it's a priority.

' ™ (an mt‑sDNA test) has been validated in multiple studies:
- 91.5% sensitivity for CRC (Thailand prospective study)
- 96.1% sensitivity vs 85.8% for FIT (ASCO GI 2023)
- Already deployed in large‑scale public health programs in China (Harbin and Ordos) reaching millions.

Today is World Digestive Health Day. Perfect timing to refocus on early detection – because stage I CRC has a over 90% 5 year survival rate; but stage IV only 14%.

Early Screening Save Lives.

📖 Read how COLOTECT™ is leading the way: https://www.bgi.com/global/news/new-us-colorectal-cancer-screening-guidelines-prioritize-stool-dna-tests-bgi-genomics-colotect

🩸🎗️Blood cancer – and in particular – is not one cancer. It's many.Four main types (AML, ALL, CLL, CML) each have dist...
28/05/2026

🩸🎗️Blood cancer – and in particular – is not one cancer. It's many.

Four main types (AML, ALL, CLL, CML) each have distinct biology and behavior. Even within the same type, molecular profiles vary widely.

That's why global guidelines recommend MICM (morphology, immunology, cytogenetics, and molecular biology). Only by seeing the full genomic picture can we guide precise, targeted intervention.

' SENTIS™ Leukemia Gene Detection delivers that molecular layer with two tailored options:
🔬 DNA+RNA – 373 genes + 1,000+ fusions (SNVs, InDels, CNVs, fusions)
🔬 DNA – 183 core genes for prognostic & hereditary risk

From newly diagnosed to relapse, pre‑transplant to remission monitoring – comprehensive genomics guides targeted therapy, risk stratification, and MRD tracking.

On today, Let's read it right.

👇 Learn more
https://www.bgi.com/global/news/bgi-genomics-sentis-leukemia-gene-detection-changing-leukemia-care

📢 You're invited to join us at - 15th International Symposium on Antimicrobial Agents and ResistanceAntimicrobial resi...
28/05/2026

📢 You're invited to join us at - 15th International Symposium on Antimicrobial Agents and Resistance

Antimicrobial resistance (AMR) is one of the most urgent global health threats. How can genomics help fight back?

📅Date: June 12–14, 2026
📌Venue: Hong Kong Convention and Exhibition Centre (HKCEC), Wanchai, Hong Kong
📍Booth D04

Discover how BGI Genomics' SIROmics™ AI-Powered Localized High-Throughput Sequencing Solution supports faster, smarter AMR detection and surveillance.

What SIROmics™ can offer:
🧬 High-throughput method for detecting hundreds to thousands of pathogens, including drug resistance and virulence genes.
🧬 Fully automated and intelligent NGS workflow solution for clinical labs
🧬 Actionable insights to guide treatment and infection control

👉 Register & learn more: https://www.isaar2026.org/

Come talk to our team. Let’s explore how AI-powered sequencing can strengthen your strategy.

See you in Hong Kong! 🇭🇰

Meet Genos‑m: an ‑source DNA foundation model built for human‑associated microbes. 🧬🤖BGI Genomics, BGI · Research and Z...
27/05/2026

Meet Genos‑m: an ‑source DNA foundation model built for human‑associated microbes. 🧬🤖

BGI Genomics, BGI · Research and Zhejiang Lab just released Genos‑m – designed specifically for the microbial world inside and around us (commensals, pathogens, phages, across major body sites).

Open source (Apache 2.0) on and .

Why it matters:
✅ Sparse MoE architecture (4.7B params, only ~330M activated) – efficient & powerful
✅ 1 Mbp context – from short genes to whole genomes
✅ Outperforms or matches much larger general‑purpose models (even Evo2‑40B)
✅ Real‑world impact: colorectal cancer risk modelling, and stable embeddings from as few as 10,000 metagenomic reads

👇 More about the Genos-m model:
https://www.bgi.com/global/news/genos-m-is-now-open-source:-a-dna-foundation-model-for-human-associated-microbial-genomes

Adresse

Ole Maaløes Vej 3
Copenhagen
2200

Telefon

+4581730146

Internet side

Underretninger

Vær den første til at vide, og lad os sende dig en email, når BGI Genomics sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Virksomheden

Send en besked til BGI Genomics:

Genveje

Del

Type